Home | Welcome to Contract Pharma   
Last Updated Monday, July 28 2014
Print RSS Feed

Topics - Drug Discovery


Refine by Date:
From: To:
Published July 15, 2014
To employ Fluofarma discovery and translational services Read More »
Published July 8, 2014
Expands Evotec's drug discovery platform Read More »
Published July 3, 2014
To establish library of more than 200,000 compounds Read More »
Published June 23, 2014
Transitions compound into preclinical development Read More »
Published June 11, 2014
X-Chem to apply discovery engine to identify novel leads Read More »
Published June 5, 2014
Will share R&D rights to gene editing technology Read More »
Published June 4, 2014
Shire invests $20.4 million in arGEN-X Read More »
Published June 4, 2014
Will continue to explore new approaches in metabolic disease Read More »
Published May 15, 2014
Adds high-throughput screening, drug combination sciences and bioinformatics expertise Read More »
Published May 9, 2014
Will use CRISPR/Cas9 gene editing system for research applications Read More »
Published May 9, 2014
Aims to develop new experimental cancer models Read More »
Published May 7, 2014
Will align Pharmorphix and BioTools for comprehensive chiral technology services Read More »
Published May 7, 2014
Adds early phase development and CMC services Read More »
Published May 6, 2014
Evotec will employ its drug discovery platform to identify a clinical candidate Read More »
Published May 2, 2014
Will evaluate the microbiome in metabolic diseases Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On